Abraxis BioScience, Inc. Reports First Quarter 2007 Revenue of $212.2 Million Versus $144.5 Million in Prior Year Period

LOS ANGELES--(BUSINESS WIRE)--The numerical amounts for depreciation and amortization expense reported in the “Consolidated Statements of Operating Highlights by Segment” tables for the quarters ended March 31, 2007 and 2006 have been corrected in this revised press release. No other changes have been made to the news release that was originally issued earlier this morning.

MORE ON THIS TOPIC